Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671411 · ClinicalTrials.gov registry record · Phase 1
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00671411: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00671411 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671411, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or malignant. Patterns of blood flow in the kidney mass will be examined to see if: 1. benign kidney masses can be distinguished from kidney cancers and 2. if slow growing, lower risk cancers have different blood flow compared to clear cell cancer which is the most common type of kidney cancer.
Interventions
- DRUG Ultrasound with intravenous microbubble contrast injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671411
The ClinicalTrials.gov registry entry for NCT00671411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ultrasound with intravenous microbubble contrast injection is the first listed.
NCT00671411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671411 about?
NCT00671411 is a clinical study titled "Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast". The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or malignant. Patterns of blood flow in the kidney mass will be examined to see if...
What is the current status of trial NCT00671411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00671411?
The interventions under investigation include: Ultrasound with intravenous microbubble contrast injection (DRUG).
Who is sponsoring clinical trial NCT00671411?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.